IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas

American Journal of Surgical Pathology

Volumn 35, Issue 6, 2011, Pages 868-872

  Zhang, Liping ^a   Liu, Yuxin ^a   Hao, Suyang ^a   Woda, Bruce A ^a   Lu, Di ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

endometrial adenocarcinoma; endometrioid carcinoma; IMP2; serous carcinoma

Indexed keywords

IMMP2L PROTEIN, HUMAN; PROTEINASE; TUMOR MARKER;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CYSTADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; PATHOLOGY;

CARCINOMA, ENDOMETRIOID; CELL COUNT; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ENDOPEPTIDASES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 79958018638     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318219c6f9     Document Type: Article

References (25)

1. Brants JR, Ayoubi TA, Chada K, et al. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett. 2004; 569:277-283. (Pubitemid 38844632)
2. Brown L. Pathology of uterine malignancies. Clin Oncol (R Coll Radiol). 2008;20:433-447.
3. Carmon KS, Loose DS. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res. 2008;6:1017-1028.
4. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-333. (Pubitemid 46986071)
5. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578. (Pubitemid 39564961)
6. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57-85. (Pubitemid 46448060)
7. Fader AN, Boruta D, Olawaiye AB, et al. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010;22:21-29.
8. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791. (Pubitemid 46630943)
9. Ioffe OB. Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol. 2005;124(suppl): S42-S51.
10. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564. (Pubitemid 43923666)
11. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551-558. (Pubitemid 28272707)
12. Li C, Zota V, Woda BA, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20:1263-1268. (Pubitemid 350126850)
13. Lu D, Vohra P, Chu PG, et al. An Oncofetal Protein IMP3, A new molecular marker for the detection of esophageal adenocarcinoma and high grade dysplasia. Am J Surg Pathol. 2009; 33:521-525.
14. McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12: 6373-6378. (Pubitemid 44799707)
15. McCluggage WG. Recent advances in immunohistochemistry in gynaecological pathology. Histopathology. 2002;40:309-326. (Pubitemid 34595581)
16. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733. (Pubitemid 27283112)
17. Nasir A, Boulware D, Kaiser HE, et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007;21:35-43.
18. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001;234:93-99. (Pubitemid 33043632)
19. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270. (Pubitemid 29046868)
20. Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:984013.
21. Peiró G, Lohse P, Mayr D, et al. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol. 2003;120:78-85. (Pubitemid 37046373)
22. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007;39:72-87.
23. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701-1706. (Pubitemid 351469454)
24. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37:1465-1472. (Pubitemid 44584324)
25. Yemelyanova A, Ji H, Shih IeM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504-1514.